Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | HSF1 | Q00613 | 5/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 5/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6462866 | 0.83 | FAAH (0.38) | XDHHSF1FAAHCES1CTSS | |
| SCHEMBL7047097 | 0.82 | AR (0.35) | ARFAAHKDM4EMAPTCES1 | |
| SCHEMBL7043202 | 0.80 | P2RY14 (0.37) | RAB9AXDHHSF1FAAHKDM4E | |
| SCHEMBL6465108 | 0.78 | XDH (0.39) | NPC1RAB9ASMN1; SMN2XDHHSF1 | |
| SCHEMBL7046391 | 0.78 | FAAH (0.37) | RAB9AXDHFAAHKDM4ECES1 | |
| SCHEMBL6468438 | 0.77 | FAAH (0.40) | XDHHSF1FAAHCES1CTSS | |
| SCHEMBL7045892 | 0.75 | CTSS (0.41) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL7046208 | 0.74 | CTSS (0.38) | FAAHCES1CTSSCYP3A4CYP2C9 | |
| SCHEMBL7046210 | 0.74 | CTSS (0.38) | FAAHCES1CTSSCYP3A4CYP2C9 | |
| SCHEMBL7116648 | 0.74 | CTSS (0.43) | CTSSCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | NPC1 428/4885TP53 375/4885RAB9A 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.